Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The results of analysis of correlations (R Spearman and p value) between particular FA and grouped FA with PASI, disease duration, BMI, CRP, cholesterol, triglyceride, glucose, vitamin D are given separately for non-obese in Table 3 and for obese psoriatic patients in Table 4.Correlation of fatty acids with clinical and laboratory data in non-obese psoriatic patients (BMI <30)Fatty acidPASIDisease durationBMICRPCholestTGFBGVit DMyristic (14:0)−0.140.130.30*−0.180.45***0.59***0.220.14Palmitic (16:0)−0.100.030.28*−0.160.63***0.62***0.260.07Palmitoleic (16:1n-7)0.080.050.100.060.31*0.250.05−0.08Stearic (18:0)−0.08−0.010.24−0.200.67***0.52***0.39**0.03Oleic (18:1n9c)0.010.000.21−0.060.53***0.74***0.260.01Linoleic (18:2n-6)−0.13−0.100.17−0.200.75***0.45***0.200.02Arachidic (20:0)−0.100.070.19−0.070.60***0.35*0.45***0.06α-Linolenic (18:3n-3)−0.13−0.160.28*−0.190.37**0.57***0.230.29*Behenic (22:0)−0.120.020.03−0.070.55***0.130.210.02Arachidonic (20:4n-6)−0.190.120.22−0.250.56***0.32*0.37**−0.02Lignoceric (24:0)−0.240.06−0.09−0.29*0.56***−0.070.100.11Eicozapentaenoic (20:5n-3)−0.210.130.31*−0.27*0.49***0.160.220.37**Nervonic (24:1n-9)0.030.08−0.040.100.50***−0.020.16−0.03Docozaheksaenoic (22:6n-3)−0.27*−0.070.36**−0.250.66***0.48***0.36**0.34**Total−0.100.010.29*−0.190.72***0.65***0.29*0.07n-3 PUFA−0.30*−0.030.39**−0.31*0.65***0.45***0.35*0.40**n-6 PUFA−0.18−0.050.21−0.26*0.79***0.44**0.260.04n-6/n-3 ratio0.23−0.01−0.33*0.20−0.33*−0.25−0.21−0.48***%SFA0.010.26*0.080.010.000.090.13−0.08%MUFA0.26*0.040.050.26−0.020.42**−0.00−0.12%PUFA−0.20−0.06−0.12−0.28*0.07−0.35*0.000.12SFA/UFA0.000.250.080.010.000.090.13−0.08Spearman’s R is shownThe significant correlations are marked as: * p < 0.05; ** p < 0.01; *** p < 0.001 PASI Psoriasis Area and Severity Index, BMI Body Mass Index, CRP C-reactive protein, Cholest cholesterol, TG triglycerides, FBG fasting blood glucose, Vit D vitamin D Correlation of fatty acids with clinical and laboratory data in obese psoriatic patients (BMI ≥30)Fatty acidPASIDisease durationBMICRPCholestTGFBGVit DMyristic (14:0)−0.140.110.28−0.040.340.71***0.240.23Palmitic (16:0)0.07−0.020.290.080.52*0.81***0.140.31Palmitoleic (16:1n-7)−0.11−0.110.210.090.280.61**0.280.01Stearic (18:0)0.16−0.090.240.000.67***0.56**−0.010.31Oleic (18:1n9c)0.160.000.310.090.380.88***0.070.11Linoleic (18:2n-6)0.04−0.060.13−0.170.71***0.36−0.280.37Arachidic (20:0)−0.09−0.48*−0.11−0.040.52*−0.180.01−0.12α-Linolenic (18:3n-3)0.030.020.42*−0.020.57**0.71***−0.000.11Behenic (22:0)−0.23−0.140.01−0.130.55**−0.22−0.050.10Arachidonic (20:4n-6)0.03−0.40*0.090.040.390.270.15−0.05Lignoceric (24:0)−0.22−0.14−0.06−0.230.59**−0.31−0.080.18Eicozapentaenoic (20:5n-3)−0.300.000.070.130.51*−0.060.270.23Nervonic (24:1n-9)0.13−0.31−0.030.180.64**−0.28−0.010.17Docozaheksaenoic (22:6n-3)−0.17−0.36−0.010.070.52*0.270.170.18Total0.020.060.320.060.66***0.73***0.090.35n-3 PUFA−0.21−0.250.080.110.58**0.300.190.18n-6 PUFA0.09−0.140.15−0.120.74***0.42−0.210.29n-6/n-3 ratio0.300.200.00−0.15−0.24−0.06−0.37−0.05%SFA0.080.100.090.17−0.230.47*0.290.14%MUFA0.29−0.160.110.26−0.020.75***0.27−0.32%PUFA−0.05−0.06−0.04−0.090.16−0.62**−0.340.03SFA/UFA0.020.160.080.13−0.250.43*0.310.19Spearman’s R is shownThe significant correlations are marked as: * p < 0.05; ** p < 0.01; *** p < 0.001 PASI Psoriasis Area and Severity Index, BMI Body Mass Index, CRP C-reactive protein, Cholest cholesterol, TG triglycerides, FBG fasting blood glucose, Vit D vitamin D
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Serum fatty acid profile in psoriasis and its comorbidity
Study design awaiting verification · Archives of Dermatological Research · 2017
Original publication title
Serum fatty acid profile in psoriasis and its comorbidity
© The Author(s) 2017
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Psoriasis is a chronic inflammatory skin disease that is accompanied by metabolic disturbances and cardio-metabolic disorders. Fatty acids (FAs) might be a link between psoriasis and its comorbidity. The aim of the study was to evaluate serum concentrations of FAs and to investigate their association with the disease activity, markers of inflammation and possible involvement in psoriatic comorbidity: obesity, type 2 diabetes and hypertension. We measured 14 total serum fatty acids content and composition by gas: liquid chromatography and flame-ionization detector after direct in situ transesterification in 85 patients with exacerbated plaque psoriasis and in 32 healthy controls.
FAs were grouped according to their biologic properties to saturated FA (SFA), unsaturated FA (UFA), monounsaturated FA (MUFA), n-3 polyunsaturated FA (n-3 PUFA) and n-6 PUFA. Generally, patients characteristic included: Psoriasis Area and Severity Index (PASI), Body Mass Index, inflammatory and biochemical markers, lipid profile and presence of psoriatic comorbidity. We have observed highly abnormal FAs pattern in psoriatic patients both with and without obesity compared to the control group. We have demonstrated association of PASI with low levels of circulating DHA, n-3 PUFA (p = 0.044 and p = 0.048, respectively) and high percent of MUFA (p = 0.024) in the non-obese psoriatic group.
The SFA/UFA ratio increased with the duration of the disease (p = 0.03) in all psoriatic patients. These findings indicate abnormal FAs profile in psoriasis which may reflect metabolic disturbances and might play a role in the psoriatic comorbidity.
Authors’ abstract
Psoriasis is a chronic inflammatory skin disease that is accompanied by metabolic disturbances and cardio-metabolic disorders. Fatty acids (FAs) might be a link between psoriasis and its comorbidity. The aim of the study was to evaluate serum concentrations of FAs and to investigate their association with the disease activity, markers of inflammation and possible involvement in psoriatic comorbidity: obesity, type 2 diabetes and hypertension. We measured 14 total serum fatty acids content and composition by gas: liquid chromatography and flame-ionization detector after direct in situ transesterification in 85 patients with exacerbated plaque psoriasis and in 32 healthy controls.
FAs were grouped according to their biologic properties to saturated FA (SFA), unsaturated FA (UFA), monounsaturated FA (MUFA), n-3 polyunsaturated FA (n-3 PUFA) and n-6 PUFA. Generally, patients characteristic included: Psoriasis Area and Severity Index (PASI), Body Mass Index, inflammatory and biochemical markers, lipid profile and presence of psoriatic comorbidity. We have observed highly abnormal FAs pattern in psoriatic patients both with and without obesity compared to the control group. We have demonstrated association of PASI with low levels of circulating DHA, n-3 PUFA (p = 0.044 and p = 0.048, respectively) and high percent of MUFA (p = 0.024) in the non-obese psoriatic group.
The SFA/UFA ratio increased with the duration of the disease (p = 0.03) in all psoriatic patients. These findings indicate abnormal FAs profile in psoriasis which may reflect metabolic disturbances and might play a role in the psoriatic comorbidity.
Publication and source details
Original title: Serum fatty acid profile in psoriasis and its comorbidity
Hanna Myśliwiec; Anna Baran; Ewa Harasim-Symbor; Piotr Myśliwiec; Anna Justyna Milewska; Adrian Chabowski; Iwona Flisiak
Archives of Dermatological Research · 2017
© The Author(s) 2017https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.http://dx.doi.org/10.13039/501100005297Uniwersytet Medyczny w BialymstokuNo: N/ST/ZB/16/001/1149Myśliwiec HannaRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T19:39:04.623381+00:00
DOI: 10.1007/s00403-017-1748-x · PMC5486566